AKBA - Akebia Therapeutics, Inc.
| Previous Close | 4.3000 |
| Open | 4.2500 |
| Bid | 4.1300 x 4000 |
| Ask | 4.1700 x 3200 |
| Day's Range | 4.1200 - 4.3950 |
| 52 Week Range | 3.5000 - 10.4500 |
| Volume | 447,853 |
| Avg. Volume | 798,363 |
| Market Cap | 494.474M |
| Beta (3Y Monthly) | 1.96 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.3950 |
| Earnings Date | Nov 6, 2019 - Nov 11, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 17.48 |
- Benzinga
The Daily Biotech Pulse: Akebia Sues CMS, Roche Raises Guidance Yet Again, Titan Medical Entangled In Credit Crunch
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Oct. 15) Celgene Corporation (NASDAQ: CELG ) Eagle Pharmaceuticals ...
- Business Wire
Akebia Files Lawsuit Against CMS for 2018 Action Rescinding Medicare Part D Coverage of FDA-Approved Auryxia® for its Iron Deficiency Anemia Indication and Imposing a Prior Authorization Requirement for its Hyperphosphatemia Indication
Akebia Therapeutics, Inc. (AKBA), a fully integrated biopharmaceutical company focused on bettering the lives of people impacted by kidney disease, today filed a complaint in federal district court against the Centers for Medicare & Medicaid Services (CMS) and the U.S. Department of Health and Human Services (HHS). The lawsuit challenges a September 2018 decision by CMS that rescinded Medicare Part D coverage of Auryxia® (ferric citrate), Akebia’s FDA-approved drug, when used for the treatment of iron deficiency anemia (IDA) in adult patients with chronic kidney disease (CKD) not on dialysis (the IDA Indication).
- Business Wire
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Akebia Therapeutics, Inc. (AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for people living with kidney disease, granted seven newly-hired employees options to purchase an aggregate of 43,600 shares of Akebia’s common stock on September 30, 2019, as inducements material to each such employee’s entering into employment with Akebia. The options have an exercise price of $3.92 per share, which is equal to the closing price of Akebia’s common stock on the grant date. Each stock option vests over four years, with 25% of the shares vesting on the first anniversary of the grant date and the remaining 75% of shares vesting quarterly thereafter, in each case, subject to the new employee’s continued service with the company.
- Simply Wall St.
Should You Worry About Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) CEO Pay Cheque?
John Butler became the CEO of Akebia Therapeutics, Inc. (NASDAQ:AKBA) in 2013. This report will, first, examine the...
- Business Wire
Akebia Therapeutics to Present at the 2019 Cantor Global Healthcare Conference
Akebia Therapeutics, Inc. (AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for people living with kidney disease, today announced that John P. Butler, President and Chief Executive Officer of Akebia, will present at the 2019 Cantor Global Healthcare Conference at 8:55 a.m. ET on Thursday, October 3, 2019 in New York City. Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company focused on the development and commercialization of therapeutics for people living with kidney disease.
- Thomson Reuters StreetEvents
Edited Transcript of AKBA earnings conference call or presentation 8-Aug-19 1:00pm GMT
Q2 2019 Akebia Therapeutics Inc Earnings Call
- Simply Wall St.
How Does Akebia Therapeutics, Inc. (NASDAQ:AKBA) Affect Your Portfolio Volatility?
If you own shares in Akebia Therapeutics, Inc. (NASDAQ:AKBA) then it's worth thinking about how it contributes to the...
Motley FoolAkebia Therapeutics, Inc. (AKBA) Q2 2019 Earnings Call Transcript
AKBA earnings call for the period ending June 30, 2019.
- Zacks
Akebia Therapeutics (AKBA) Reports Q2 Loss, Tops Revenue Estimates
Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of 14.29% and 14.09%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
- Zacks
Akebia Therapeutics (AKBA) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Akebia Therapeutics (AKBA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Simply Wall St.
What Type Of Shareholder Owns Akebia Therapeutics, Inc.'s (NASDAQ:AKBA)?
The big shareholder groups in Akebia Therapeutics, Inc. (NASDAQ:AKBA) have power over the company. Institutions often...
- Simply Wall St.
When Can We Expect A Profit From Akebia Therapeutics, Inc. (NASDAQ:AKBA)?
Akebia Therapeutics, Inc.'s (NASDAQ:AKBA): Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the...
- Insider Monkey
Hedge Funds Are Dumping Akebia Therapeutics Inc (AKBA)
Hedge funds and other investment firms run by legendary investors like Israel Englander, Jeffrey Talpins and Ray Dalio are entrusted to manage billions of dollars of accredited investors' money because they are without peer in the resources they use to identify the best investments for their chosen investment horizon. Moreover, they are more willing to […]
- Thomson Reuters StreetEvents
Edited Transcript of AKBA earnings conference call or presentation 9-May-19 1:00pm GMT
Q1 2019 Akebia Therapeutics Inc Earnings Call
- Business Wire
Akebia Therapeutics Launches AkebiaCares, an Enhanced Patient Access Program for People with Chronic Kidney Disease
AkebiaCares connects patients, caregivers and health care providers with resources and important information to support greater access to therapy
